1. Expressions for Healthy Life
INTAS GROUP OF COMPANIES

2. Corporate Overview
We are…
• A leading generic Pharmaceutical manufacturing and marketing
company.
Our Vision…
• To become a leading global healthcare organisation driven by
people, research and technology
INTAS GROUP OF COMPANIES

3. Journey So Far…
2009 Crossed 340 Mn USD turnover
2007 Supplies started to US
2006 New manufacturing facility in North and East India
2005 Commenced production of Cytotoxic products
2004 Acknowledged as one of the fastest growing pharma co. in India
2001 Laid foundation of Astron Research
2000 Setting up of the Bio-pharmaceuticals unit
1995 Set up an ultra modern manufacturing facility - Matoda
1984 Commences India Marketing Operations
1976 Intas sets up 1st manufacturing unit
INTAS GROUP OF COMPANIES

4. Group Of Companies
A leading pharmaceutical company in India
Mfg Facility: Matoda, Vatva, DDN, SEZ, SIKKIM
A Leading pharmaceutical A leading biotech company
formulation and A leading clinical research in India & contract Marketing Arm of Intas
development company organisation research company worldwide.
INTAS GROUP OF COMPANIES

5. Astron Research Ltd.
• Fastest growing Pharma Contract Research Organization
• Accredited by USFDA
• MHRA approved testing laboratory in UK
• A team of 270 experienced scientist with inhouse fully
equipped development laboratory.
• Successfully developed 100+ products for regulated market.
• Capabilities include Dossier Development, Formulation
Research, Analytical Research, Regulatory Affairs & Quality
Assurance
• Expertise across various formulations like Solid Orals,
Injectables, Lyophilised injectables, Topicals, Effervescent
tablets & Oncology products
INTAS GROUP OF COMPANIES

6. Lambda Therapeutic Research Ltd.
Lambda core activities: Facilities in:
• Clinical trials (Phase I-IV) Ahmedabad 240 beds
• BA & BE studies
Mumbai 40 beds
• 300 regulatory submissions in USA,
Chennai 110 beds
• Canada, EU, Australia, Brazil
• Database of >25.000 volunteers Warsaw [ Poland ] 55 beds
INTAS GROUP OF COMPANIES

7. Intas Biopharmaceutical Ltd.
• 1st EU approved Biotechnology facility in India
• Having capabilities for manufacturing bio-recombinant and DNA based products,
Ecoli & Cell culture based technology
• Has successfully developed & launched recombinant proteins
- Neukine (rHu G-CSF) - Erykine & Epofit (rHu EPO)
- Intalfa (rHu IFN Alfa-2b) - Neupeg (Pegylated rHu G-CSF),
- world’s first Peg Filgrastim after the innovator
INTAS GROUP OF COMPANIES

8. Manufacturing Facilities
INTAS GROUP OF COMPANIES

9. Backward Integration…
APIs
• 1st eDMF : Gemcitabine
• Others : Capecitabine, Paclitaxel, Docetaxel
Temozolamide, Imatinib , Metoprolol
Succinate, Telmisartan…….
INTAS GROUP OF COMPANIES

10. Global Footprints
CANADA
UK
USA SPAIN
VIETNAM
MEXICO
PERU
INDIA (H.Q)
BRAZIL
KENYA
SOUTH AFRICA
AUSTRALIA
NEW ZEALAND
INTAS GROUP OF COMPANIES

11. Global Footprints
• 11 ANDAs Approved, 18 filed, 45 ANDAs are in Development
• 36 products approved. 20 dossiers filed in Europe. Additional 42
dossiers are in development
• Holding 1100+ live registrations in 45 countries
• Strong presence in Europe, Latin America, South Africa and
Australia
• Excellent contract manufacturing support for regulated markets
4.0 bn Tablets / Capsules manufactured during 2009 for EU
25+ satisfied partners
Handling 100+ molecules
INTAS GROUP OF COMPANIES

12. Key Partners
efiL yhtlaeH roF snoisserpxE
CR PARTNERS Dossier Sale Partners
INTAS GROUP OF COMPANIES

13. INTAS GROUP OF COMPANIES

14. SITE LAYOUT
INTAS GROUP OF COMPANIES

15. Oral solids Capacities
Dosage Form Annual Capacity Regulatory Approvals
Tablets & Capsules 5.2 Bn Tab / Cap USFDA
Effervescent Tablets 300 Mn Tablets MHRA
Narrow Therapeutic Tablets 900 Mn Tablets TGA
Pellets 30000 Kgs ANVISA
MCC
INTAS GROUP OF COMPANIES

16. Injectables Capacities
Dosage Form Annual Capacity Regulatory Approvals
Liquid Ampoules 85 Mn MHRA
Liquid Vials 30 Mn TGA
MCC
INTAS GROUP OF COMPANIES

17. Cytotoxic & Potent Dosages Capacities
Dosage Form Annual Capacity Regulatory Approvals
Tablets & Capsules 90 Mn Tab / Cap USFDA
Liquid Vials 6.5 Mn Vials MHRA
Lyophilized Vials 1.0 Mn Vials TGA
ANVISA
MCC
INTAS GROUP OF COMPANIES

18. CAPACITIES – NEW FACILITY (SEZ)
Dosage Form Annual Capacity Planned Approvals
GENERAL MHRA (May. 10)
Tablets & Capsules 6 Bn Tab/Cap USFDA (Date to finalize)
ONCOLOGY
Tablets & Capsules 200 Mn Tab/Cap
Liquid Vials 10 Mn Vials
Lyophilized Vials 8.0 Mn Vials
INTAS GROUP OF COMPANIES

19. Intas : Your partner of choice for …..
• READY DOSSIERS FOR SUBMISSION TO ANVISA WITH OR WITHOUT
COMMERCIAL SUPPLIES
• DEVELOPMENT EXPERTISE THROUGH ASTRON FOR DEVELOPMENT OF
BRAZIL DOSSIER FOR PRODUCTS OF YOUR INTEREST.
• TECHNOLOGY TRANSFER OF THE PRODUCTS DEVELOPED BY ASTRON.
• PRODUCT LIST
INTAS GROUP OF COMPANIES

20. THANK YOU!
INTAS GROUP OF COMPANIES